Rosetta Genomics (ROSG +284%) shares shoot into orbit after the microRNA-based molecular diagnostic test maker says Novitas, the designated Medicare Administrative Contractor for its miRview® mets² assay, announced it plans to cover the assay for all Medicare beneficiaries.